Trafficking and migration in tolerance

Current Opinion in Organ Transplantation

Volumn 11, Issue 4, 2006, Pages 379-384

  Ochando, Jordi C ^a   Ledgerwood, Levi G ^a   Yopp, Adam C ^a   Bromberg, Jonathan S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Chemokines; Lymph node migration; Plasmacytoid dendritic cells

Indexed keywords

FINGOLIMOD; TRANSPLANTATION ANTIGEN;

ALLOGRAFT; ANATOMY; ANTIGEN PRESENTING CELL; CELL INTERACTION; CELL MIGRATION; COMPARATIVE STUDY; DENDRITIC CELL; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE MIGRATION; LYMPHOID ORGAN; NONHUMAN; OUTCOME ASSESSMENT; REVIEW;

EID: 33746370072     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/01.mot.0000236700.29963.1a     Document Type: Review

References (51)

1. Rulifson IC, Szot GL, Palmer E, Bluestone JA. Inability to induce tolerance through direct antigen presentation. Am J Transplant 2002; 2:510-519.
2. Valujskikh A, Lantz O, Celli S, et al. Cross-primed CD8(+) T cells mediate graft rejection via a distinct effector pathway. Nat Immunol 2002; 3:844-851.
3. Itano AA, McSorley SJ, Reinhardt RL, et al. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 2003; 19:47-57.
4. Coates PT, Colvin BL, Kaneko K, et al. Pharmacologic, biologic, and genetic engineering approaches to potentiation of donor-derived dendritic cell tolerogenicity. Transplantation 2003; 75:32S-36S.
5. Chen Y, Demir Y, Valujskikh A, Heeger PS. The male minor transplantation antigen preferentially activates recipient CD4+ T cells through the indirect presentation pathway in vivo. J Immunol 2003; 171:6510-6518.
6. Reed AJ, Noorchashm H, Rostami SY, et al. Alloreactive CD4 T cell activation in vivo: an autonomous function of the indirect pathway of alloantigen presentation. J Immunol 2003; 171:6502-6509.
7. Quezada SA, Fuller B, Jarvinen LZ, et al. Mechanisms of donor-specific transfusion tolerance: preemptive induction of clonal T-cell exhaustion via indirect presentation. Blood 2003; 102:1920-1926.
8. He C, Schenk S, Zhang Q, et al. Effects of T cell frequency and graft size on transplant outcome in mice. J Immunol 2004; 172:240-247.
9. Chalasani G, Li Q, Konieczny BT, et al. The allograft defines the type of rejection (acute versus chronic) in the face of an established effector immune response. J Immunol 2004; 172:7813-7820.
10. Watarai Y, Koga S, Paolone DR, et al. Intraallograft chemokine RNA and protein during rejection of MHC-matched/multiple minor histocompatibility- disparate skin grafts. J Immunol 2000; 164:6027-6033.
11. Koga S, Auerbach MB, Engeman TM, et al. T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-gamma-induced chemokine Mig. J Immunol 1999; 163:4878-4885.
12. Lakkis FG, Arakelov A, Konieczny BT, Inoue Y. Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 2000; 6:686-688.
13. Ochando JC, Homma C, Yang Y, et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006; in press.
14. de Heer HJ, Hammad H, Soullie T, et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 2004; 200:89-98.
15. Pendl GG, Robert C, Steinert M, et al. Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. Blood 2002; 99:946-956.
16. Mirenda V, Millington O, Lechler RI, et al. Tolerant T cells display impaired trafficking ability. Eur J Immunol 2005; 35:2146-2156.
17. Richards DM, Dalheimer SL, Ehst BD, et al. Indirect minor histocompatibility antigen presentation by allograft recipient cells in the draining lymph node leads to the activation and clonal expansion of CD4+ T cells that cause obliterative airways disease. J Immunol 2004; 172:3469-3479.
18. Alvarez D, Swirski FK, Yang TC, et al. Inhalation tolerance is induced selectively in thoracic lymph nodes but executed pervasively at distant mucosal and nonmucosal tissues. J Immunol 2006; 176:2568-2580.
19. Cavanagh LL, Bonasio R, Mazo IB, et al. Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. Nat Immunol 2005; 6:1029-1037.
20. Bai Y, Liu J, Wang Y, et al. L-selectin-dependent lymphoid occupancy is required to induce alloantigen-specific tolerance. J Immunol 2002; 168:1579-1589.
21. Ochando JC, Yopp AC, Yang Y, et al. Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. J Immunol 2005; 174:6993-7005.
22. Schenk S, Kish DD, He C, et al. Alloreactive T cell responses and acute rejection of single class II MHC-disparate heart allografts are under strict regulation by CD4+ CD25+ T cells. J Immunol 2005; 174:3741-3748.
23. Karim M, Kingsley CI, Bushell AR, et al. Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process. J Immunol 2004; 172:923-928.
24. Cobbold SP, Castejon R, Adams E, et al. Induction of foxP3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol 2004; 172:6003-6010.
25. Ansel KM, Ngo VN, Hyman PL, et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000; 406:309-314.
26. Colvin BL, Wang Z, Nakano H, et al. CXCL9 antagonism further extends prolonged cardiac allograft survival in CCL19/CCL21-deficient mice. Am J Transplant 2005; 5:2104-2113.
27. Wang L, Han R, Lee I, et al. Permanent survival of fully MHC-mismatched islet allografts by targeting a single chemokine receptor pathway. J Immunol 2005; 175:6311-6318.
28. Wekerle T, Kurtz J, Bigenzahn S, et al. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 2002; 14:592-600.
29. Marski M, Kandula S, Turner JR, Abraham C. CD18 is required for optimal development and function of CD4+CD25+ T regulatory cells. J Immunol 2005; 175:7889-7897.
30. Dustin ML. Stop and go traffic to tune T cell responses. Immunity 2004; 21:305-314.
31. Hugues S, Fetler L, Bonifaz L, et al. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat Immunol 2004; 5:1235-1242.
32. Shakhar G, Lindquist RL, Skokos D, et al. Stable T cell-dendritic cell interactions precede the development of both tolerance and immunity in vivo. Nat Immunol 2005; 6:707-714. The authors indicate that there are no differences between antigen-specific dendritic cell-T-cell interactions at early stages during immunity or tolerance.
33. Tang Q, Adams JY, Tooley AJ, et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006; 7:83-92. The authors report that the control of autoimmune diabetes by Tregs in the draining lymph node involves persistent dendritic cell-Treg interaction rather than Treg suppression of effector cells.
34. Graca L, Cobbold SP, Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002; 195:1641-1646.
35. Siegmund K, Feuerer M, Siewert C, et al. Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo. Blood 2005; 106:3097-3104. The authors generated Tregs deficient in CD62E ligand and CD62P ligand and report that Treg trafficking into inflamed sites is necessary to regulate effector immune responses.
36. Lee I, Wang L, Wells AD, et al. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 2005; 201:1037-1044. The authors report that CCR4-dependent migration of Tregs into vascularized cardiac allografts is necessary to induce tolerance to vascularized allografts.
37. Jones TR, Shirasugi N, Adams AB, et al. Intravital microscopy identifies selectins that regulate T cell traffic into allografts. J Clin Invest 2003; 112:1714-1723.
38. Jiang X, Shimaoka T, Kojo S, et al. Cutting edge: critical role of CXCL16/ CXCR6 in NKT cell trafficking in allograft tolerance. J Immunol 2005; 175:2051-2055. The authors report that natural killer T cells must migrate to vascularized cardiac allografts through CXCL16 to prevent rejection.
39. Kharel Y, Lee S, Snyder AH, et al. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J Biol Chem 2005; 280:36865-36872.
40. Zemann B, Kinzel B, Muller M, et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 2006; 107:1454-1458.
41. Yan S, Rodriguez-Barbosa JI, Pabst O, et al. Protection of mouse small bowel allografts by FTY720 and costimulation blockade. Transplantation 2005; 79:1703-1710.
42. Tedesco-Silva H, Mourad G, Kahan BD, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2005; 79:1553-1560.
43. Bohler T, Waiser J, Schutz M, et al. FTY720 mediates apoptosis- independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytes. Transplantation 2004; 77:1424-1432.
44. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004; 18:551-553.
45. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427:355-360.
46. Wei SH, Rosen H, Matheu MP, et al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol 2005; 6:1228-1235. The authors report that treatment with S1P1-specific agonist blocks lymphocyte entry into medullary sinuses within lymph nodes by closing 'stromal gates' between sinus-lining endothelial cells, preventing lymphocyte egress from lymph nodes.
47. Bohler T, Waiser J, Schuetz M, et al. FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors. Nephrol Dial Transplant 2004; 19:702-713.
48. Sawicka E, Dubois G, Jarai G, et al. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J Immunol 2005; 175:7973-7980.
49. Zhang Q, Chen Y, Fairchild RL, et al. Lymphoid sequestration of alloreactive memory CD4 T cells promotes cardiac allograft survival. J Immunol 2006; 176:770-777. The authors report additional activities and consequences of FTY720 for cardiac allografts, including prevention of alloreactive memory T-cell trafficking and induction of alloantibody-mediated responses.
50. Lan YY, De Creus A, Colvin BL, et al. The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am J Transplant 2005; 5:2649-2659.
51. Briscoe DM, Sayegh MH. A rendezvous before rejection: where do T cells meet transplant antigens? Nat Med 2002; 8:220-222.